A phase III, multicenter, randomized, open-label study comparing Atezolizumab (anti-PD-L1 antibody) in combination with adjuvant anthracycline/taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.
Michail Ignatiadis, MD, PhD (Institut Jules Bordet, Université Libre de Bruxelles, Brussels)
Heather McArthur, MD (Cedars Sinai Medical Center Los Angeles, California)